Y-Mabs Therapeutics Other Current Liabilities

Y-Mabs Therapeutics (YMAB) currently reports a other current liabilities of $15M as of June 2025. That compares with $32M in the prior-year period — down 54.1% year over year. Use the charts on this page to explore Y-Mabs Therapeutics's other current liabilities history and peer comparisons.

Y-Mabs Therapeutics's other current liabilities decreased from $32M to $15M — a 54.1% year-over-year decrease (period ending June 2025). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

Y-Mabs Therapeutics reported $15M in other current liabilities as of June 2025. That compares with $32M in the prior-year period — down 54.1% year over year. Absolute dollar amounts are most useful when compared with prior periods, peers, and related line items such as revenue, assets, or liabilities on Stockcircle.

Start with the current other current liabilities of $15M, then check the historical chart for trend and the peer comparison chart for relative positioning. From there, open related valuation or income-statement pages for Y-Mabs Therapeutics, and consider following YMAB for alerts when major investors trade the stock.

Y-Mabs Therapeutics is classified in the Healthcare sector. On other current liabilities, it currently shows $15M. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing YMAB with unrelated industries.